度洛西汀和帕罗西汀联合羟考酮缓释片治疗晚期癌痛伴抑郁的疗效比较

曾媛; 孙建海

doi:10.16016/j.1000-5404.202005052

您当前的位置：

首页 >

文章列表页 >

度洛西汀和帕罗西汀联合羟考酮缓释片治疗晚期癌痛伴抑郁的疗效比较

神经科学 | 更新时间：2026-01-09

- 度洛西汀和帕罗西汀联合羟考酮缓释片治疗晚期癌痛伴抑郁的疗效比较
- Curative effect of oxycodone sustained-release tablets combined with duloxetine versus paroxetine in treatment of depression and pain from advanced cancer
- 第三军医大学学报 2020年42卷第19期页码：1890-1897
- 作者机构：
- 作者简介：
- 基金信息：
  
  江汉大学研究生科研创新基金项目(YKYCXJJYX18006)
- DOI：10.16016/j.1000-5404.202005052
  中图分类号：
- 收稿：2020-05-08，
  
  纸质出版：2020-10-15
- 稿件说明：
移动端阅览
曾媛, 孙建海. 度洛西汀和帕罗西汀联合羟考酮缓释片治疗晚期癌痛伴抑郁的疗效比较[J]. 第三军医大学学报, 2020,42(19):1890-1897.

Yuan ZENG, Jianhai SUN. Curative effect of oxycodone sustained-release tablets combined with duloxetine versus paroxetine in treatment of depression and pain from advanced cancer[J]. Journal of Third Military Medical University, 2020, 42(19): 1890-1897.
曾媛, 孙建海. 度洛西汀和帕罗西汀联合羟考酮缓释片治疗晚期癌痛伴抑郁的疗效比较[J]. 第三军医大学学报, 2020,42(19):1890-1897. DOI： 10.16016/j.1000-5404.202005052.

Yuan ZENG, Jianhai SUN. Curative effect of oxycodone sustained-release tablets combined with duloxetine versus paroxetine in treatment of depression and pain from advanced cancer[J]. Journal of Third Military Medical University, 2020, 42(19): 1890-1897. DOI： 10.16016/j.1000-5404.202005052.

摘要

Abstract

Objective

To investigate the efficacy and safety of oxycodone sustained-release tablets combined with different types of antidepressants (duloxetine and paroxetine) in the patients suffering from depression and pain due to advanced cancer.

Methods

A total of 108 depressive patients with advanced cancer pain in admitted in Hubei Third People's Hospital from July 2018 to September 2019 were recruited in this study. They were divided into 3 groups single-blindly and randomly

with 36 subjects in each group. The patients from Group A were given oxycodone sustained-release tablets only

those out of Group B the tablets+paroxetine

and those of Group C the tablets+duloxetine. Pain relief

depression

anxiety

dose of oxycodone

sleep quality

quality of life and adverse reactions were compared among the 3 groups after treatment.

Results

After treatment of 1 week

the numeric rating scale (NRS) score of Group C was significantly lower than those of Group B and A (

0.05). The NRS score and self-rating anxiety scale (SAS) score at 2 weeks after treatment

and the self-rating depression scale (SDS) score at 1 week after treatment were significantly decreased in a trend from Group A to Group B to Group C (all

0.05). But the

re were no obvious differences in the NRS

SAS and SDS scores at 1 and 2 months after treatment

and the SDS score at 2 weeks after treatment between Group C and B (

0. 05)

and all of these scores were notably lower than those of Group A (

0. 05). After treatment of 2 months

the average daily oral dose of oxycodone per capita in Group A and B were significantly higher than that before treatment (

0.05)

but no such difference was seen in Group C (

0.05). The score of Pittsburgh sleep quality index (PSQI) were remarkably decreased in the 3 groups after treatment (

0.05). But no significant differences were seen in the average daily oral dose of oxycodone per capita and the PSQI score between Group B and C

but the dose and score were both significantly lower than those of Group A (

0.05). In 2 months after treatment

the scores of different items of quality of life score were significantly increased in the 3 groups (

0.05)

but except for the role function score

there were no differences in other scores between Group C and B (

0.05)

and the scores were significantly higher than those of Group A (

0.05). After treatment of 2 months

the adverse reactions had no significant differences among the 3 groups (

0.05)

and were gradually reduced or disappeared after symptomatic treatment or dose adjustment.

Conclusion

In the treatment of depressive patients with pain from advanced cancer

oxycodone sustained-release tablets combined with duloxetine is superior to paroxetine in quick onset

effective improvement of pain

depression

anxiety and quality of sleep and life

and reduced dose of oxycodone

and does not increase adverse reactions.

关键词

Keywords

references

ZHAO X X CUI M GENG Y H A systematic review and meta-analysis of randomized controlled trials of palliative care for pain among Chinese adults with cancer BMC Palliat Care 2019 18 1 69 10.1186/s12904-019-0456-z ZHAO X X, CUI M, GENG Y H, et al . A systematic review and meta-analysis of randomized controlled trials of palliative care for pain among Chinese adults with cancer[J ] . BMC Palliat Care, 2019, 18(1): 69. DOI:10.1186/s12904-019-0456-z.

SHOVAL G BALICER R D FELDMAN B Adherence to antidepressant medications is associated with reduced premature mortality in patients with cancer: a nationwide cohort study Depress Anxiety 2019 36 10 921 929 10.1002/da.22938 SHOVAL G, BALICER R D, FELDMAN B, et al . Adherence to antidepressant medications is associated with reduced premature mortality in patients with cancer: a nationwide cohort study[J ] . Depress Anxiety, 2019, 36(10): 921-929. DOI:10.1002/da.22938.

SANFORD N N SHER D J BUTLER S S Prevalence of chronic pain among cancer survivors in the United States, 2010-2017 Cancer 2019 125 23 4310 4318 10.1002/cncr.32450 SANFORD N N, SHER D J, BUTLER S S, et al . Prevalence of chronic pain among cancer survivors in the United States, 2010-2017[J ] . Cancer, 2019, 125(23): 4310-4318. DOI:10.1002/cncr.32450.

KHEMIRI S BEN THABET J BEN KRIDIS W Psychoaffective repercussions of pain in cancer patients Cancer Radiother 2019 23 3 188 193 10.1016/j.canrad.2018.09.002 KHEMIRI S, BEN THABET J, BEN KRIDIS W, et al . Psychoaffective repercussions of pain in cancer patients[J ] . Cancer Radiother, 2019, 23(3): 188-193. DOI:10.1016/j.canrad.2018.09.002.

SHENG J Y LIU S WANG Y C The link between depression and chronic pain: neural mechanisms in the brain Neural Plast 2017 2017 9724371 10.1155/2017/9724371 SHENG J Y, LIU S, WANG Y C, et al . The link between depression and chronic pain: neural mechanisms in the brain[J ] . Neural Plast, 2017, 2017: 9724371. DOI:10.1155/2017/9724371.

燕晓茹陈恂张培彤近十年癌性抑郁相关危险因素研究现状中医杂志 2018 59 19 1694 1698 10.13288/j.11-2166/r.2018.19.019 燕晓茹, 陈恂, 张培彤.近十年癌性抑郁相关危险因素研究现状[J].中医杂志, 2018, 59(19): 1694-1698. DOI:10.13288/j.11-2166/r.2018.19.019.

YAN X R CHEN X ZHANG P T Research status of risk factors related to cancer depression in recent ten years J Tradit Chin Med 2018 59 19 1694 1698 10.13288/j.11-2166/r.2018.19.019 YAN X R, CHEN X, ZHANG P T. Research status of risk factors related to cancer depression in recent ten years[J]. J Tradit Chin Med, 2018, 59(19): 1694-1698. DOI:10.13288/j.11-2166/r.2018.19.019.

GRASSI L NANNI M G RODIN G The use of antidepressants in oncology: a review and practical tips for oncologists Ann Oncol 2018 29 1 101 111 10.1093/annonc/mdx526.[PubMed GRASSI L, NANNI M G, RODIN G, et al . The use of antidepressants in oncology: a review and practical tips for oncologists[J ] . Ann Oncol, 2018, 29(1): 101-111. DOI:10.1093/annonc/mdx526.[PubMed ]

曾媛孙建海阿片类药物联用抗抑郁药治疗晚期癌痛伴抑郁的研究进展江汉大学学报(自然科学版) 2020 48 2 41 47 10.16389/j.cnki.cn42-1737/n.2020.02.007 曾媛, 孙建海.阿片类药物联用抗抑郁药治疗晚期癌痛伴抑郁的研究进展[J].江汉大学学报(自然科学版), 2020, 48(2): 41-47. DOI:10.16389/j.cnki.cn42-1737/n.2020.02.007.

ZENG Y SUN J H Progress in diagnosis and treatment on pain with depression in advanced cancer J Jianghan Univ (Nat Sci Ed) 2020 48 2 41 47 10.16389/j.cnki.cn42-1737/n.2020.02.007 ZENG Y, SUN J H. Progress in diagnosis and treatment on pain with depression in advanced cancer[J]. J Jianghan Univ (Nat Sci Ed), 2020, 48(2): 41-47. DOI:10.16389/j.cnki.cn42-1737/n.2020.02.007.

LUNN M P HUGHES R A WIFFEN P J Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia Cochrane Database Syst Rev 2014 1 1 CD007115 10.1002/14651858.cd007115.pub3 LUNN M P, HUGHES R A, WIFFEN P J. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia[J]. Cochrane Database Syst Rev, 2014, 1(1): CD007115. DOI:10.1002/14651858.cd007115.pub3.

MUSCATELLO M R A ZOCCALI R A PANDOLFO G Duloxetine in psychiatric disorders: expansions beyond major depression and generalized anxiety disorder Front Psychiatry 2019 10 772 10.3389/fpsyt.2019.00772 MUSCATELLO M R A, ZOCCALI R A, PANDOLFO G, et al . Duloxetine in psychiatric disorders: expansions beyond major depression and generalized anxiety disorder[J ] . Front Psychiatry, 2019, 10: 772. DOI:10.3389/fpsyt.2019.00772.

GAYNOR P J GOPAL M ZHENG W A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms Curr Med Res Opin 2011 27 10 1849 1858 10.1185/03007995.2011.609539 GAYNOR P J, GOPAL M, ZHENG W, et al . A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms[J ] . Curr Med Res Opin, 2011, 27(10): 1849-1858. DOI:10.1185/03007995.2011.609539.

谢旖静张鹏帕罗西汀对老年骨折伴焦虑抑郁患者术后心理状态及疼痛介质的影响中国药物警戒 2017 14 10 590 593 10.3969/j.issn.1672-8629.2017.10.004 谢旖静, 张鹏.帕罗西汀对老年骨折伴焦虑抑郁患者术后心理状态及疼痛介质的影响[J].中国药物警戒, 2017, 14(10): 590-593. DOI:10.3969/j.issn.1672-8629.2017.10.004.

XIE Y J ZHANG P Effect of paroxetine on postoperative psychological state and pain mediators in eldly fractured patients with anxiety and depression Chin J Pharmacovigil 2017 14 10 590 593 10.3969/j.issn.1672-8629.2017.10.004 XIE Y J, ZHANG P. Effect of paroxetine on postoperative psychological state and pain mediators in eldly fractured patients with anxiety and depression[J]. Chin J Pharmacovigil, 2017, 14(10): 590-593. DOI:10.3969/j.issn.1672-8629.2017.10.004.

朱晓波常快乐李文心理干预联合帕罗西汀治疗慢性疼痛伴焦虑和抑郁效果观察人民军医 2019 62 10 958 960 http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=rmjy201910020 朱晓波, 常快乐, 李文.心理干预联合帕罗西汀治疗慢性疼痛伴焦虑和抑郁效果观察[J].人民军医, 2019, 62(10): 958-960.

ZHU X B CHANG K L LI W Effect of psychological intervention combined with paroxetine in the treatment of chronic pain with anxiety and depression People Mil Surg 2019 62 10 958 960 http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=rmjy201910020 ZHU X B, CHANG K L, LI W. Effect of psychological intervention combined with paroxetine in the treatment of chronic pain with anxiety and depression[J]. People Mil Surg, 2019, 62(10): 958-960.

闫秀玲帕罗西汀治疗癌症晚期患者疼痛的临床疗效中国医师进修杂志 2012 35 27 53 55 10.3760/cma.j.issn.1673-4904.2012.27.021 闫秀玲.帕罗西汀治疗癌症晚期患者疼痛的临床疗效[J].中国医师进修杂志, 2012, 35(27): 53-55. DOI:10.3760/cma.j.issn.1673-4904.2012.27.021.

YAN X L Clinical efficacy of paroxetine in the treatment of pain in patients with advanced cancer Chin J Postgraduates Med 2012 35 27 53 55 10.3760/cma.j.issn.1673-4904.2012.27.021 YAN X L. Clinical efficacy of paroxetine in the treatment of pain in patients with advanced cancer[J]. Chin J Postgraduates Med, 2012, 35(27): 53-55. DOI:10.3760/cma.j.issn.1673-4904.2012.27.021.

WANG Z Y XU X F TAN Q R Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial Shanghai Arch Psychiatry 2015 27 4 228 236 10.11919/j.issn.1002-0829.215064 WANG Z Y, XU X F, TAN Q R, et al . Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial[J ] . Shanghai Arch Psychiatry, 2015, 27(4): 228-236. DOI:10.11919/j.issn.1002-0829.215064.

THALER K J MORGAN L C VAN NOORD M Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review Depress Anxiety 2012 29 6 495 505 10.1002/da.21951 THALER K J, MORGAN L C, VAN NOORD M, et al . Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review[J ] . Depress Anxiety, 2012, 29(6): 495-505. DOI:10.1002/da.21951.

HONG J NOVICK D MONTGOMERY W Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia Asia-Pac Psychiatry 2016 8 1 51 59 10.1111/appy.12178 HONG J, NOVICK D, MONTGOMERY W, et al . Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia[J ] . Asia-Pac Psychiatry, 2016, 8(1): 51-59. DOI:10.1111/appy.12178.

张艳唐茂芹度洛西汀与帕罗西汀治疗伴有疼痛症状的抑郁障碍的对照研究中国药房 2011 22 12 1087 1089 http://www.cnki.com.cn/Article/CJFDTotal-ZGYA201112018.htm 张艳, 唐茂芹.度洛西汀与帕罗西汀治疗伴有疼痛症状的抑郁障碍的对照研究[J].中国药房, 2011, 22(12): 1087-1089.

ZHANG Y TANG M Q Comparative study of dutoxetine vs. paroxetine in the treatment of pain symptom in patients with depressive disorders China Pharm 2011 22 12 1087 1089 http://www.cnki.com.cn/Article/CJFDTotal-ZGYA201112018.htm ZHANG Y, TANG M Q. Comparative study of dutoxetine vs. paroxetine in the treatment of pain symptom in patients with depressive disorders[J]. China Pharm, 2011, 22(12): 1087-1089.

ARMOOGUM J HARCOURT D FOSTER C The experience of persistent pain in adult cancer survivors: a qualitative evidence synthesis Eur J Cancer Care 2020 29 1 10.1111/ecc.13192 ARMOOGUM J, HARCOURT D, FOSTER C, et al . The experience of persistent pain in adult cancer survivors : a qualitative evidence synthesis[J ] . Eur J Cancer Care, 2020, 29(1): e13192. DOI:10.1111/ecc.13192.

KIM H J MALONE P S Roles of biological and psychosocial factors in experiencing a psychoneurological symptom cluster in cancer patients Eur J Oncol Nurs 2019 42 97 102 10.1016/j.ejon.2019.08.005 KIM H J, MALONE P S. Roles of biological and psychosocial factors in experiencing a psychoneurological symptom cluster in cancer patients[J]. Eur J Oncol Nurs, 2019, 42: 97-102. DOI:10.1016/j.ejon.2019.08.005.

黄菁巫云立沈红梅癌性疼痛伴抑郁状态的治疗进展重庆医学 2019 48 7 1188 1190, 1195 10.3969/j.issn.1671-8348.2019.07.026 黄菁, 巫云立, 沈红梅.癌性疼痛伴抑郁状态的治疗进展[J].重庆医学, 2019, 48(7): 1188-1190, 1195. DOI:10.3969/j.issn.1671-8348.2019.07.026.

HUANG J WU Y L SHEN H M Advances in treatment of cancer pain with depression Chongqing Med 2019 48 7 1188 1190, 1195 10.3969/j.issn.1671-8348.2019.07.026 HUANG J, WU Y L, SHEN H M. Advances in treatment of cancer pain with depression[J]. Chongqing Med, 2019, 48(7): 1188-1190, 1195. DOI:10.3969/j.issn.1671-8348.2019.07.026.

OSTUZZI G BENDA L COSTA E Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysis Cancer Treat Rev 2015 41 8 714 724 10.1016/j.ctrv.2015.06.003 OSTUZZI G, BENDA L, COSTA E, et al . Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysis[J ] . Cancer Treat Rev, 2015, 41(8): 714-724. DOI:10.1016/j.ctrv.2015.06.003.

SWARM R A PAICE J A ANGHELESCU D L Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology J Natl Compr Cancer Netw 2019 17 8 977 1007 10.6004/jnccn.2019.0038 SWARM R A, PAICE J A, ANGHELESCU D L, et al . Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology[J ] . J Natl Compr Cancer Netw, 2019, 17(8): 977-1007. DOI:10.6004/jnccn.2019.0038.

OSTUZZI G MATCHAM F DAUCHY S Antidepressants for the treatment of depression in people with cancer Cochrane Database Syst Rev 2018 4 4 CD011006 10.1002/14651858.CD011006.pub3 OSTUZZI G, MATCHAM F, DAUCHY S, et al . Antidepressants for the treatment of depression in people with cancer[J ] . Cochrane Database Syst Rev, 2018, 4(4): CD011006. DOI: 10.1002/14651858.CD011006.pub3

李秀玉王晓静腰向颖癌性疼痛与抑郁障碍转化医学杂志 2013 2 1 48 50 10.3969/j.issn.2095-3097.2013.01.013 李秀玉, 王晓静, 腰向颖, 等.癌性疼痛与抑郁障碍[J].转化医学杂志, 2013, 2(1): 48-50. DOI:10.3969/j.issn.2095-3097.2013.01.013.

LI X Y WANG X J YAO X Y Cancer pain and depression Transl Med J 2013 2 1 48 50 10.3969/j.issn.2095-3097.2013.01.013 LI X Y, WANG X J, YAO X Y, et al . Cancer pain and depression[J ] . Transl Med J, 2013, 2(1): 48-50. DOI:10.3969/j.issn.2095-3097.2013.01.013.

秦保健李琳度洛西汀与帕罗西汀治疗以躯体疼痛为主诉的老年抑郁症患者的对照研究国际医药卫生导报 2017 23 17 2749 2751 10.3760/cma.j.issn.1007-1245.2017.17.030 秦保健, 李琳.度洛西汀与帕罗西汀治疗以躯体疼痛为主诉的老年抑郁症患者的对照研究[J].国际医药卫生导报, 2017, 23(17): 2749-2751. DOI:10.3760/cma.j.issn.1007-1245.2017.17.030.

QIN B J LI L Duloxetine versus paroxtine for elderly patients with depression whose main symptom was body pain Int Med Heal Guid News 2017 23 17 2749 2751 10.3760/cma.j.issn.1007-1245.2017.17.030 QIN B J, LI L. Duloxetine versus paroxtine for elderly patients with depression whose main symptom was body pain[J]. Int Med Heal Guid News, 2017, 23(17): 2749- 2751. DOI:10.3760/cma.j.issn.1007-1245.2017.17.030.

MARTINEZ J M KATON W GREIST J H A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode Int Clin Psychopharmacol 2012 27 1 17 26 10.1097/YIC.0b013e32834ce11b MARTINEZ J M, KATON W, GREIST J H, et al . A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode[J ] . Int Clin Psychopharmacol, 2012, 27(1): 17-26. DOI:10.1097/YIC.0b013e32834ce11b.[LinkOut ]

朱建峰金卫东孙峰俐度洛西汀治疗抑郁症临床疗效及安全性国内研究的meta分析中华行为医学与脑科学杂志 2018 27 9 858 864 10.3760/cma.j.issn.1674-6554.2018.09.018 朱建峰, 金卫东, 孙峰俐.度洛西汀治疗抑郁症临床疗效及安全性国内研究的meta分析[J].中华行为医学与脑科学杂志, 2018, 27(9): 858-864. DOI:10.3760/cma.j.issn.1674-6554.2018.09.018.

ZHU J F JIN W D SUN F L Efficacy and safety of duloxetine for depression in China: a meta-analysis Chin J Behav Med Brain Sci 2018 27 9 858 864 10.3760/cma.j.issn.1674-6554.2018.09.018 ZHU J F, JIN W D, SUN F L. Efficacy and safety of duloxetine for depression in China: a meta-analysis[J]. Chin J Behav Med Brain Sci, 2018, 27(9): 858-864. DOI:10.3760/cma.j.issn.1674-6554.2018.09.018.

汪品嘉李鑫姚文秀癌性神经病理性疼痛的辅助镇痛药物研究进展实用医药杂志 2019 36 1 77 80 10.14172/j.issn1671-4008.2019.01.027 汪品嘉, 李鑫, 姚文秀.癌性神经病理性疼痛的辅助镇痛药物研究进展[J].实用医药杂志, 2019, 36(1): 77-80. DOI:10.14172/j.issn1671-4008.2019.01.027.

WANG P J LI X YAO W X Current medication of cancerous neuropathic pain by using adjuvant analgesics Pract J Med Pharm 2019 36 1 77 80 10.14172/j.issn1671-4008.2019.01.027 WANG P J, LI X, YAO W X. Current medication of cancerous neuropathic pain by using adjuvant analgesics[J]. Pract J Med Pharm, 2019, 36(1): 77-80. DOI:10.14172/j.issn1671-4008.2019.01.027.

YOON S Y OH J Neuropathic cancer pain: prevalence, pathophysiology, and management Korean J Intern Med 2018 33 6 1058 1069 10.3904/kjim.2018.162 YOON S Y, OH J. Neuropathic cancer pain: prevalence, pathophysiology, and management[J]. Korean J Intern Med, 2018, 33(6): 1058-1069. DOI:10.3904/kjim.2018.162.

GUAN J TANAKA S KAWAKAMI K Anticonvulsants or antidepressants in combination pharmacotherapy for treatment of neuropathic pain in cancer patients: a systematic review and meta-analysis Clin J Pain 2016 32 8 719 725 10.1097/AJP.0000000000000310 GUAN J, TANAKA S, KAWAKAMI K. Anticonvulsants or antidepressants in combination pharmacotherapy for treatment of neuropathic pain in cancer patients: a systematic review and meta-analysis[J]. Clin J Pain, 2016, 32(8): 719-725. DOI:10.1097/AJP.0000000000000310.

崔剑陈建平郭芳盐酸羟考酮缓释片在中重度成人癌痛门诊治疗中的疗效及安全性山西医科大学学报 2018 49 3 297 301 10.13753/j.issn.1007-6611.2018.03.019 崔剑, 陈建平, 郭芳, 等.盐酸羟考酮缓释片在中重度成人癌痛门诊治疗中的疗效及安全性[J].山西医科大学学报, 2018, 49(3): 297-301. DOI:10.13753/j.issn.1007-6611.2018.03.019.

CUI J CHEN J P GUO F Efficacy and safety of oxycodone hydrochloride sustained release tablet in outpatient treatment of moderate or severe adult cancer pain J Shanxi Med Univ 2018 49 3 297 301 10.13753/j.issn.1007-6611.2018.03.019 CUI J, CHEN J P, GUO F, et al . Efficacy and safety of oxycodone hydrochloride sustained release tablet in outpatient treatment of moderate or severe adult cancer pain[J ] . J Shanxi Med Univ, 2018, 49(3): 297-301. DOI:10.13753/j.issn.1007-6611.2018.03.019.

YENNURAJALINGAM S TAYJASANANT S BALACHANDRAN D Association between daytime activity, fatigue, sleep, anxiety, depression, and symptom burden in advanced cancer patients: a preliminary report J Palliat Med 2016 19 8 849 856 10.1089/jpm.2015.0276 YENNURAJALINGAM S, TAYJASANANT S, BALACHANDRAN D, et al . Association between daytime activity, fatigue, sleep, anxiety, depression, and symptom burden in advanced cancer patients: a preliminary report[J ] . J Palliat Med, 2016, 19(8): 849-856. DOI:10.1089/jpm.2015.0276.

YENNURAJALINGAM S KANG D H HWU W J Cranial electrotherapy stimulation for the management of depression, anxiety, sleep disturbance, and pain in patients with advanced cancer: a preliminary study J Pain Symptom Manag 2018 55 2 198 206 10.1016/j.jpainsymman.2017.08.027 YENNURAJALINGAM S, KANG D H, HWU W J, et al . Cranial electrotherapy stimulation for the management of depression, anxiety, sleep disturbance, and pain in patients with advanced cancer: a preliminary study[J ] . J Pain Symptom Manag, 2018, 55(2): 198-206. DOI:10.1016/j.jpainsymman.2017.08.027.

KWEKKEBOOM K L ZHANG Y Z CAMPBELL T C Randomized controlled trial of a brief cognitive-behavioral strategies intervention for the pain, fatigue, and sleep disturbance symptom cluster in advanced cancer Psycho-oncology 2018 27 12 2761 2769 10.1002/pon.4883 KWEKKEBOOM K L, ZHANG Y Z, CAMPBELL T C, et al . Randomized controlled trial of a brief cognitive-behavioral strategies intervention for the pain, fatigue, and sleep disturbance symptom cluster in advanced cancer[J ] . Psycho-oncology, 2018, 27(12): 2761-2769. DOI:10.1002/pon.4883.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

正念注意觉知在抑郁合并失眠患者知觉压力与抑郁情绪间的中介作用

我国退役军人抑郁症状特点及相关因素分析

抑郁情绪对高原新兵新训期睡眠质量的影响：负性认知加工偏向的纵向调节作用

基于误导信息干扰范式抑郁情绪个体虚假记忆特点的行为学研究